4D Molecular Therapeutics FDMT Cash Flow Statement (2019-2026)

NASDAQ FDMT
$12.62 -0.48 (-3.66%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

4D Molecular Therapeutics Quarterly Cash Flow Statement

Periods 27 quarters
Latest Jun 2026

4D Molecular Therapeutics reported cash from operations of -$70.00M and free cash flow of -$70.00M for the quarter ended Jun 2026, down 61.4% year over year. This cash flow statement covers 27 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-22.24M-25.08M-26.34M-28.09M-25.69M-27.38M-28.68M-29.62M-10.26M-32.28M-32.40M-34.95M-43.84M-49.67M-47.97M-54.66M-56.88M19.40M-68.76M-72.94M
Depreciation and DepletionDep. & Depletion
0.40M0.40M0.40M0.50M0.50M1.00M1.00M1.10M1.10M1.30M1.20M1.20M1.20M1.20M1.30M1.30M1.30M1.30M1.30M1.30M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.38M0.39M0.41M0.47M0.52M1.01M1.03M1.08M0.99M1.10M1.17M1.19M1.19M1.10M1.05M1.17M1.26M1.22M1.27M1.28M
Share-based CompensationStock Comp.
3.92M3.73M3.93M4.32M4.52M4.35M4.22M4.97M4.56M5.91M5.97M6.07M6.49M7.58M6.99M4.96M4.52M5.55M4.45M5.88M
Gains from Sales and DivestituresGains Divest
Other non-cash itemsOther Non-Cash
0.39M0.38M0.38M0.37M0.35M0.37M0.39M0.34M0.56M0.41M0.42M0.44M0.53M0.70M0.62M0.73M0.75M0.78M0.80M0.82M
Change in Working Capital
Change in ReceivablesChange Receivables
-0.43M-0.74M-0.05M
Change in Account PayablesChange Payables
0.80M1.66M-1.68M0.23M-1.70M1.51M-0.33M0.95M1.37M-1.09M0.70M-0.79M-0.51M1.46M-0.24M4.55M-1.84M4.30M3.53M-4.06M
Change in Accured ExpensesChange Accured Exp.
1.06M0.54M-1.07M0.65M1.08M1.82M-3.40M1.16M3.61M2.00M-2.39M3.17M8.11M-2.37M-2.31M3.11M4.98M2.37M-4.12M6.54M
Change in Other Operating AssetsOther Assets Change
-0.52M5.40M-1.02M-1.64M-0.58M2.02M0.02M0.46M1.22M-0.22M1.41M2.56M-1.28M2.59M3.86M1.28M-2.76M2.97M4.66M6.51M
Change in Other Operating LiabilitiesOther Liabilities Change
-1.00M0.47M-0.85M0.02M-0.95M-1.68M-0.74M-0.29M-0.67M-0.47M-0.42M-0.52M-0.41M-0.23M-0.77M-0.79M-0.90M-0.94M0.50M-0.08M
Other Working Capital ChangesOther WC Changes
-0.48M-4.93M0.17M1.66M-0.36M-3.69M-0.76M-0.75M-1.89M-0.25M-1.83M-3.08M0.87M-2.81M-4.62M-2.07M1.85M-3.91M-4.16M-6.59M
Cash from OperationsCash from Ops.
-15.72M-21.84M-23.55M-19.90M-21.02M-22.21M-27.91M-22.07M-1.17M-24.65M-29.09M-30.24M-29.39M-45.86M-47.76M-43.38M-46.50M28.55M-68.13M-70.00M
Investing Activities
Capital ExpendituresCapex
2.64M5.10M6.41M2.07M1.96M1.09M1.01M0.81M0.41M0.55M0.71M0.35M1.78M0.95M0.63M0.07M-0.09M-0.07M
Change in Property, Plant and EquipmentChange in PP&E
-2.64M-5.10M-6.41M-2.07M-1.96M-1.09M-1.01M-0.81M-0.41M-0.55M-0.71M-0.35M-1.78M-0.95M-0.63M-0.07M0.09M0.07M
Purchase of InvestmentsInvestments Purchased
136.38M32.20M59.69M6.19M187.94M-100.51M14.73M5.43M34.65M277.32M96.76M35.79M57.78M134.08M115.40M15.24M178.10M33.52M62.04M
Sale and Maturity of InvestmentsInvestments Sold
5.00M12.00M65.72M205.28M-135.19M58.87M55.52M30.39M28.51M14.78M23.57M64.87M65.79M166.66M101.62M32.93M49.18M102.40M87.65M
Cash from Investing ActivitiesCash from Investing
-139.01M-32.29M-54.11M57.47M15.37M-35.78M43.13M49.29M29.98M-6.68M-263.26M-73.54M27.30M7.06M31.95M-13.85M17.78M-128.85M68.89M25.54M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
1.98M114.76M0.88M0.06M-0.37M2.16M1.42M0.61M1.04M4.24M3.11M0.85M0.57M0.05M0.00M0.12M9.48M1.67M0.11M
Net Shares Issued and RepurchasedNet Shares Issued
1.98M114.76M0.88M0.06M-0.37M2.16M1.42M0.61M1.04M4.24M3.11M0.85M0.57M0.05M0.00M0.12M9.48M1.67M0.11M
Net Equity Issued and RepurchasedNet Equity Issued
1.98M114.76M0.88M0.06M-0.37M2.16M1.42M0.61M1.04M4.24M3.11M0.85M0.57M0.05M0.00M0.12M9.48M1.67M0.11M
Other financing activitiesOther financing
0.95M-0.25M-0.11M0.36M-0.47M-0.07M-0.47M
Cash from Financing ActivitiesCash from Financing
1.98M116.14M0.63M-0.05M0.46M2.05M10.99M130.52M10.56M4.76M318.83M17.25M0.57M0.60M0.86M0.12M111.98M11.48M42.34M
Additional items
Change in Cash
-152.75M62.01M-77.03M37.51M-5.19M-55.95M26.22M157.74M39.37M-26.57M26.49M-86.53M-1.52M-38.20M-15.81M-56.37M-28.60M11.69M12.25M-2.12M
Ending Cash Balance
90.99M153.00M75.97M113.48M108.30M52.35M78.57M236.31M275.68M249.11M275.59M189.06M187.54M149.34M133.53M77.16M48.56M60.24M72.49M70.37M
Free Cash FlowFCF
-18.36M-26.93M-29.96M-21.97M-22.98M-23.31M-28.92M-22.87M-1.58M-25.20M-29.80M-30.59M-31.17M-46.81M-48.39M-43.44M-46.41M28.62M-68.13M-70.00M
Net Cash FlowNCF
-152.75M62.01M-77.03M37.51M-5.19M-55.95M26.22M157.74M39.37M-26.57M26.49M-86.53M-1.52M-38.20M-15.81M-56.37M-28.60M11.69M12.25M-2.12M

4D Molecular Therapeutics Cash Flow Statement API

Pull 4D Molecular Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=FDMT&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY